Cargando…

Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial

BACKGROUND: Although Hizentra is indicated for immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies, phase III trials have focused on patients with primary immunodeficiencies. In this 9-month, real-life, prospective, non-interventional, longitudinal, multicent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Viallard, J. F., Agape, P., Barlogis, V., Cozon, G., Faure, C., Fouyssac, F., Gaud, C., Gourin, M. P., Hamidou, M., Hoarau, C., Husseini, F., Ojeda-Uribe, M., Pavic, M., Pellier, I., Perlat, A., Schleinitz, N., Slama, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041334/ https://www.ncbi.nlm.nih.gov/pubmed/27687879 http://dx.doi.org/10.1186/s12865-016-0169-5

Ejemplares similares

Safety and Efficacy of Hizentra® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies
por: Patel, Niraj C., et al.
Publicado: (2023)

Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS)
por: Vultaggio, Alessandra, et al.
Publicado: (2018)

A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions?
por: Pasquet, Marlène, et al.
Publicado: (2017)

Efficacy and Safety of Hizentra(®), a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency
por: Borte, Michael, et al.
Publicado: (2011)

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies
por: Mallick, Rajiv, et al.
Publicado: (2018)

Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort “Visages”
por: Bienvenu, B., et al.
Publicado: (2016)

Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials
por: Jolles, Stephen, et al.
Publicado: (2018)

Subcutaneous Immunoglobulin Replacement Therapy with Hizentra® is Safe and Effective in Children Less Than 5 Years of Age
por: Patel, Niraj C., et al.
Publicado: (2015)

Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients
por: Bienvenu, Boris, et al.
Publicado: (2018)

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
por: Martin, Adriana, et al.
Publicado: (2012)

Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study
por: Mielke, Orell, et al.
Publicado: (2019)

A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States
por: Mallick, Rajiv, et al.
Publicado: (2023)

Functions of Tfh Cells in Common Variable Immunodeficiency
por: Le Saos-Patrinos, Corentin, et al.
Publicado: (2020)

In-depth interviews of patients with primary immunodeficiency who have experienced pump and rapid push subcutaneous infusions of immunoglobulins reveal new insights on their preference and expectations
por: Cozon, Grégoire Jacques Noël, et al.
Publicado: (2018)

Altered dendritic cell distribution in patients with common variable immunodeficiency
por: Viallard, Jean-François, et al.
Publicado: (2005)

Case Report: Zellweger Syndrome and Humoral Immunodeficiency: The Relevance of Newborn Screening for Primary Immunodeficiency
por: Fazi, C., et al.
Publicado: (2022)

Combined Immunodeficiency in Patients With Trichohepatoenteric Syndrome
por: Vély, Frédéric, et al.
Publicado: (2018)

Gelatin-Thrombin Matrix: A New and Simple Way to Manage Recurrent Epistaxis in Hematology Units
por: Buiret, G., et al.
Publicado: (2013)

T-cell activation discriminates subclasses of symptomatic primary humoral immunodeficiency diseases in adults
por: Picat, Marie-Quitterie, et al.
Publicado: (2014)

Animal immunodeficiency viruses
por: Egberink, H., et al.
Publicado: (1992)

Coenzyme Q(10) deficiencies: pathways in yeast and humans
por: Awad, Agape M., et al.
Publicado: (2018)

PReS-FINAL-2025: Arthritis associated with human immunodeficiency virus
por: Bean, AE, et al.
Publicado: (2013)

EVER2 protein binds TRADD to promote TNF-α-induced apoptosis
por: Gaud, G, et al.
Publicado: (2013)

Physical parameters of fabrics which contribute in wetness sensation throughout a high-intensity exercise in a warm environment
por: Agapé, Florence
Publicado: (2015)

Beyond drug‐induced alteration of glutamate homeostasis, astrocytes may contribute to dopamine‐dependent intrastriatal functional shifts that underlie the development of drug addiction: A working hypothesis
por: Fouyssac, Maxime, et al.
Publicado: (2019)

PRKDC mutations associated with immunodeficiency, granuloma and aire-dependent autoimmunity
por: Belot, Alexandre, et al.
Publicado: (2014)

P1632: PROSPECTIVE OBSERVATIONAL STUDY IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) TREATED WITH TPO-R AGONISTS (TPO-RA): ELTROMBOPAG (EPAG) AND ROMIPLOSTIM (ROMI) - THE PEPITE STUDY
por: Chèze, S., et al.
Publicado: (2022)

Intragenic suppressor mutations of the COQ8 protein kinase homolog restore coenzyme Q biosynthesis and function in Saccharomyces cerevisiae
por: Awad, Agape M., et al.
Publicado: (2020)

Whole-Genome Sequences of Two NDM-1-Producing Pseudomonas aeruginosa Strains Isolated in a Clinical Setting in Albania in 2018
por: Tafaj, Silva, et al.
Publicado: (2020)

Low Circulating Natural Killer Cell Counts are Associated With Severe Disease in Patients With Common Variable Immunodeficiency
por: Ebbo, Mikael, et al.
Publicado: (2016)

Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden
por: Pincez, Thomas, et al.
Publicado: (2021)

Histoplasmosis as a presentation of human immunodeficiency virus infection.
por: Carey, F. M., et al.
Publicado: (2002)

Molecular Evidence of Genome Editing in a Mouse Model of Immunodeficiency
por: Abdul-Razak, H. H., et al.
Publicado: (2018)

New Insights into Human Cytomegalovirus pUL52 Structure
por: Muller, Clotilde, et al.
Publicado: (2021)

Contemporary management of advanced laryngeal cancer
por: Britt, Christopher J., et al.
Publicado: (2017)

Anti-CMV therapy, what next? A systematic review
por: Gourin, Claire, et al.
Publicado: (2023)

Thoracic involvement and imaging patterns in IgG4-related disease
por: Muller, Romain, et al.
Publicado: (2021)

Combined Immunodeficiency Associated with DOCK8 Mutations and Related Immunodeficiencies
por: Su, Helen C.
Publicado: (2010)

Feline Immunodeficiency Virus in South America
por: Teixeira, Bruno M., et al.
Publicado: (2012)

Retrospective TREC testing of newborns with Severe Combined Immunodeficiency and other primary immunodeficiency diseases
por: Jilkina, O., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_33mefjli6i8rps91frj26joqs4